-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Empirical evidence suggests that rituximab is a third-line option for refractory systemic muscle weakness (MG), but its effect on emerging disease is unknown
.
The randomized, double-blind, placebo-controlled study was conducted in 7 regional clinics in Sweden for 48 weeks
.
The results showed that of the 87 patients who may have been eligible, 25 were randomly assigned to rituximab (mean [SD] age, 67.
In summary, a single dose of 500 mg of rituximab is associated
with a greater probability of minimal MG performance and reduced need for rescue drugs compared with placebo.
References:
Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial.